Biological barriers to cellular delivery of lipid-based DNA carriers

被引:144
|
作者
Bally, MB
Harvie, P
Wong, FMP
Kong, S
Wasan, EK
Reimer, DL
机构
[1] Univ British Columbia, Fac Med, British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Univ British Columbia, Fac Med, Dept Pathol & Lab Med, Vancouver, BC V5Z 4E6, Canada
关键词
DNA transfer; transfection; cationic lipids; gene therapy;
D O I
10.1016/S0169-409X(99)00034-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although lipid-based DNA delivery systems are being assessed in gene therapy clinical trials, many investigators in this field are concerned about the inefficiency of lipid-based gene transfer technology, a criticism directed at all formulations used to enhance transfer of plasmid expression vectors. It is important to recognize that many approaches have been taken to improve transfection efficiency, however because of the complex nature of the formulation technology being developed, it has been extremely difficult to define specific carrier attributes that enhance transfection. We believe that these optimization processes are flawed for two reasons. First, a very defined change in formulation components affects the physical and chemical characteristics of the carrier in many ways. As a consequence, it has not been possible to define structure/activity relationships. Second, the primary endpoint used to assess plasmid delivery has been transgene expression, an activity that is under the control of cellular processes that have nothing to do with delivery. Gene expression following administration of a plasmid expression vector involves a number of critical steps: (i) DNA protection, (ii) binding to a specific cell population, (iii) DNA transfer across the cell membrane, (iv) release of DNA into the cytoplasm, (v) transport through the cell and across the nuclear membrane as well as (vi) transcription and translation of the gene. The objective of this review is to describe lipid-based DNA carrier systems and the attributes believed to be important in regulating the transfection activity of these formulations. Although membrane destabilization activity of the lipid-based carriers plays an important role, we suggest here that a critical element required for efficient transfection is dissociation of lipids bound to the plasmid expression vector following internalization. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:291 / 315
页数:25
相关论文
共 50 条
  • [21] Lipid-Based Nanocarriers for RNA Delivery
    Xue, Hui Yi
    Guo, Pengbo
    Wen, Wu-Cheng
    Wong, Ho Lun
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (22) : 3140 - 3147
  • [22] Lipid-Based Nanoformulations for Active Delivery
    Das, Surajit
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2015, 16 (04) : 289 - 290
  • [23] Lipid-based antigen delivery systems
    Park J.Y.
    Kim M.-G.
    Shim G.
    Oh Y.-K.
    Journal of Pharmaceutical Investigation, 2016, 46 (4) : 295 - 304
  • [24] Lipid-based nanoformulations for peptide delivery
    Matougui, Nada
    Boge, Lukas
    Groo, Anne-Claire
    Umerska, Anita
    Ringstad, Lovisa
    Bysell, Helena
    Saulnier, Patrick
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 502 (1-2) : 80 - 97
  • [25] Lipid-Based Drug Delivery Systems
    Shrestha, Hina
    Bala, Rajni
    Arora, Sandeep
    JOURNAL OF PHARMACEUTICS, 2014, 2014
  • [26] Lipid-based vectors for siRNA delivery
    Zhang, Shubiao
    Zhi, Defu
    Huang, Leaf
    JOURNAL OF DRUG TARGETING, 2012, 20 (09) : 724 - 735
  • [27] Lipid-based systemic delivery of siRNA
    Tseng, Yu-Cheng
    Mozumdar, Subho
    Huang, Leaf
    ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (09) : 721 - 731
  • [28] Lipid-based nanotherapeutics for siRNA delivery
    Schroeder, A.
    Levins, C. G.
    Cortez, C.
    Langer, R.
    Anderson, D. G.
    JOURNAL OF INTERNAL MEDICINE, 2010, 267 (01) : 9 - 21
  • [29] Lipid-based nanocarriers challenging the ocular biological barriers: Current paradigm and future perspectives
    Abla, Kawthar K.
    Mehanna, Mohammed M.
    JOURNAL OF CONTROLLED RELEASE, 2023, 362 : 70 - 96
  • [30] Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery
    Buck, Jonas
    Grossen, Philip
    Cullis, Pieter R.
    Huwyler, Jorg
    Witzigmann, Dominik
    ACS NANO, 2019, 13 (04) : 3754 - 3782